User profiles for Maximilian Stahl
 | Maximilian StahlDana-Farber Cancer Institute, Harvard University Verified email at dfci.harvard.edu Cited by 2908 |
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Azacitidine + venetoclax, decitabine + venetoclax, and low-dose cytarabine + venetoclax
are now standard treatments for newly diagnosed older or unfit patients with acute myeloid …
are now standard treatments for newly diagnosed older or unfit patients with acute myeloid …
[PDF][PDF] Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia
Therapy resistance is a major challenge in the treatment of cancer. Here, we performed
CRISPR-Cas9 screens across a broad range of therapies used in acute myeloid leukemia to …
CRISPR-Cas9 screens across a broad range of therapies used in acute myeloid leukemia to …
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable
clinical presentations and outcomes. The initial response criteria developed by the …
clinical presentations and outcomes. The initial response criteria developed by the …
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of
older acute myeloid leukemia (AML) patients, little is known about their effectiveness in …
older acute myeloid leukemia (AML) patients, little is known about their effectiveness in …
Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells
Many cancers carry recurrent, change-of-function mutations affecting RNA splicing factors.
Here, we describe a method to harness this abnormal splicing activity to drive splicing factor …
Here, we describe a method to harness this abnormal splicing activity to drive splicing factor …
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Most studies of immunosuppressive therapy (IST) in myelodysplastic syndromes (MDS) are
limited by small numbers and their single-center nature, and report conflicting data regarding …
limited by small numbers and their single-center nature, and report conflicting data regarding …
Differentiation syndrome in acute promyelocytic leukaemia
M Stahl, MS Tallman - British journal of haematology, 2019 - Wiley Online Library
Acute promyelocytic leukaemia differentiation syndrome (APL DS) is seen when patients
with APL are treated with all‐trans retinoic acid (ATRA) and/or arsenic trioxide (ATO). …
with APL are treated with all‐trans retinoic acid (ATRA) and/or arsenic trioxide (ATO). …
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Immunotherapy has revolutionized therapy in both solid and liquid malignancies. The ability
to cure acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an …
to cure acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an …
[HTML][HTML] Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a …
The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome
coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection …
coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection …